Stuart J Pocock, João Pedro Ferreira, Timothy J Collier, Christiane E Angermann, Jan Biegus, Sean P Collins, Mikhail Kosiborod, Michael E Nassif, Piotr Ponikowski, Mitchell A Psotka, John R Teerlink, Jasper Tromp, John Gregson, Jonathan P Blatchford, Cordula Zeller, Adriaan A Voors
AIMS: The EMPULSE trial evaluated the clinical benefit of empagliflozin versus placebo using the stratified win ratio approach in 530 patients with acute heart failure (HF) after initial stabilization. We aim to elucidate how this method works and what it means, thereby giving guidance for use of the win ratio in future trials. METHODS AND RESULTS: The primary trial outcome is a hierarchical composite of death, number of HF events, time to first HF event, or a ≥5-point difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score change at 90 days...
April 10, 2023: European Journal of Heart Failure